RELAPSE OF NEW WORLD DIFFUSE CUTANEOUS LEISHMANIASIS CAUSED BY \textit{LEISHMANIA (LEISHMANIA) MEXICANA} AFTER MILTEFOSINE TREATMENT

MANUEL CALVPINIA, EDUARDO A. GOMEZ, HERBERT SINDERMANN, PHILIP J. COOPER, AND YOSHIISSHA HASHIGUCHI

Department of Parasitology, Kochi Medical School, Kochi University, Kochi, Japan; Departamento de Epidemiologia, Instituto Nacional de Higiene y Medicina Tropical Leopoldo Izquieta Perez, Guayaquil, Ecuador; Medical Research and Development, Zentaris, Frankfurt, Germany; Laboratorio de Investigaciones, Hospital Pedro Vicente Maldonado, Pichincha Province, Ecuador

Abstract. A 35-year-old man with a 19-year history of slowly evolving diffuse cutaneous leishmaniasis was treated with oral miltefosine. 50 mg three times a day. The patient responded after four months of miltefosine treatment with clearance of all nodular lesions and plaques from the entire body surface and had negative slit-skin smears and cultures for \textit{Leishmania}. However, two months after stopping miltefosine, skin lesions reappeared and parasites were observed in samples. The relapsed lesions did not respond to an additional two-month course of miltefosine. No laboratory or clinical adverse events to miltefosine were observed. Parasites from skin lesions were cultured and identified as \textit{Leishmania (Leishmania) mexicana} by isoenzyme electrophoresis.

INTRODUCTION

Current chemotherapy for leishmaniasis has never been so promising with the introduction of new drugs and formulations such as miltefosine and liposomal amphotericin B. However, the usefulness of these new compounds for the treatment of the rare clinical presentation of diffuse cutaneous leishmaniasis (DCL) is uncertain. New World DCL (NW-DCL) is a serious illness caused by parasites of the \textit{Leishmania} subgenus in patients with poor cell-mediated immunity (anergic) to \textit{Leishmania} parasites. Results of the skin test reaction to \textit{Leishmania} antigens (LST) in these patients are negative. NW-DCL has been reported in several countries in Central and South America, and is characterized by widely disseminated non-ulcerating skin papules, nodules, and plaques.\textsuperscript{1}

DCL never heals spontaneously and is highly resistant to chemotherapy. Currently, there is no effective treatment for NW-DCL and treatment with antimonial drugs or other drugs produces only transitory remissions.\textsuperscript{2,3} Data are limited on the clinical efficacy of oral miltefosine (hexadecylphosphocholine) for the treatment on NW-DCL. However, it has been shown to be highly effective for the treatment of visceral leishmaniasis\textsuperscript{4} and some of the New World cutaneous leishmaniasis,\textsuperscript{5} and has shown efficacy in immunocompromised patients co-infected with human immunodeficiency virus.\textsuperscript{6} In a study in Venezuela, 10 of 12 patients with NW-DCL treated with 2.0–2.5 mg/kg/day of miltefosine were \textit{Leishmania} negative after 2.5 months of treatment, but the outcome of treatment was not reported after withdrawal of miltefosine (Zerpa O and others, unpublished data). We describe a patient with DCL associated with \textit{L. (Leishmania) mexicana} infection from Ecuador whose disease resolved completely clinically and parasitologically after four months of oral miltefosine (2.5 mg/kg/day) but relapsed two months after stopping this treatment and failed to respond to a second course of miltefosine.

CASE REPORT

A 35-year-old Ecuadorian man in March 2005 had violet-brown non-ulcerated papules, nodules, and plaques distrib-
(seven months after the start of treatment), small papular lesions appeared (Figure 3) and the slit-skin smears and aspirates of lesions were positive for *Leishmania* parasites. Miltefosine was again given at same dose, but no clinical or parasitologic response was observed after two months of re-treatment, and skin lesions continued to grow and disseminate over his entire body.

**DISCUSSION**

New World DCL has been reported in the United States, Mexico, Dominican Republic, Honduras, Venezuela, Colombia, French Guyana, Brazil, Peru, Paraguay, and Bolivia.\(^1,11\) The *Leishmania* species most commonly associated with DCL in the New World is *L. (L.) amazonensis*,\(^1\) although cases associated with *L. (L.) mexicana* and *L. (V.) panamensis* infection have been reported in Mexico and Colombia.\(^12,13\)

A single, standard, high-dose course of pentavalent antimonial drugs is the recommended chemotherapy for the leishmaniases in the New World.\(^14\) However, with the exception of an anecdotal case in Colombia,\(^13\) no patient with DCL has been cured with this treatment regimen even after administration of several courses of treatment, as demonstrated in the present case who had received approximately 480 ampules of antimony by the time of the initiation of treatment with miltefosine. Numerous other options have been evaluated for the treatment of NW-DCL, including local heat treatment,\(^3\) gamma-interferon in combination with pentamidine and allopurinol,\(^2\) or pentavalent antimony.\(^15\) Immunotherapy using *Leishmania* antigens plus bacillus Calmette-Guérin or in combination with antimoniate meglumine appeared to be useful in Venezuelan patients with early lesions of DCL,\(^4\) but only produced clinical improvement in patients with chronic infection.\(^5\) In the present case, we used the alternative drug pentamidine, but this was discontinued because of adverse reactions. Mefloquine and artemisinin, which have been reported to be effective for the treatment of localized cutaneous leishmaniasis (CL) in Ecuador,\(^15\) were used also in this case with partial improvement in skin lesions, but there was no clinical response to itraconazole.

The efficacy of miltefosine has not been reported widely for NW-DCL, although a preliminary study provided evidence...
for clinical and parasitologic cure in 10 of 12 Venezuelan cases (Zerpa O and others, unpublished data). In the present trial, however, similar daily doses (2.5 mg/kg/day) administered for a longer period (five months) failed to cause clinical cure and complete relapse was observed two-months post-treatment. The apparent success of the Venezuelan study was not clear because follow-up data on clinical status of the subjects were not provided beyond the completion of therapy. However, most of the patients in this study relapsed after several months of apparent remission (Sindermann H, unpublished data). In the study of Zerpa and others, speciation of the parasites was not performed, and the investigators presumed that the parasite were L. mexicana complex. In our case, parasites were identified as L. (L.) mexicana. Differences in the therapeutic response to miltefosine between species of New World Leishmania have been reported in vitro and in a clinical trial. An L. (L.) mexicana isolate from Peru was not sensitive to miltefosine in a macrophage-amastigote model, and clinical cases of CL in Guatemala where L. (L.) mexicana and L. (V.) braziliensis are common were less responsive than Colombian cases.

In our subject, an early and full clinical response to miltefosine was observed, but a relapse was noted after several months. Such a promising initial clinical response but a failure to respond after the start of a second course of miltefosine could be explained by the acquisition of resistance by the parasites. Observations from India suggest that relapsing cases are resistant to miltefosine. In addition, laboratory studies have predicted that multidrug resistance could affect sensitivity to miltefosine and its analogs. Resistant promastigotes of L. donovani, the most sensitive species to miltefosine, have been generated in vitro and caused by reduced accumulation of 14C-labeled miltefosine. Point mutations in the membrane P-type transporter (LDMT gene) that is responsible for the uptake of miltefosine and glycerophospholipids have been identified that cause reduced uptake of miltefosine into promastigotes. Another species of Leishmania (L. [L.] tropica) that overexpresses a P-glycoprotein is less sensitive to miltefosine.

Although the therapeutic activity of miltefosine is considered to be a consequence of direct effects of the drug on Leishmania parasites that are independent of host immunity, the relapse of DCL in our patient after a five-month course of high-dose miltefosine may indicate that host immunity has an important role in preventing relapse.

In conclusion, although miltefosine induced an early clinical response in our patient with NW-DCL, in agreement with a previous study in Venezuela, the high risk of relapse indicates a need for investigating new drug combinations or maintenance regimens. Because cell-mediated immunity against Leishmania parasites is poor or absent in patients with DCL, combination treatments of miltefosine with agents that increase host immune responses such as immunotherapy should be considered.

Received June 23, 2006. Accepted for publication August 19, 2006.

Acknowledgments: We are indebted to the patient for permitting publication of his case and photographs, and to Roberto Sud for technical assistance.

Financial support: This study was supported by the Ministry of Education, Science, Culture and Sports of Japan (grants no. 14256002 and 18256004).

Authors’ addresses: Manuel Calvopina and Yoshihisa Hashiguchi, Department of Parasitology, Kochi Medical School, Kochi University, Kochi 783-8505, Japan, Telephone: 81-88-880-2417, Fax: 81-88-880-2415. E-mails: mcalvopina@hotmail.com and hashiguy@med.kochi-u.ac.jp. Eduardo A. Gomez, Departamento de Epidemiología, Instituto Nacional de Higiene y Medicina Tropical Leopoldo Izquieta Perez, Apartado 10853, Guayaquil, Ecuador, Telephone and fax: 593-42-362709, E-mail: egolandires@yahoo.es. Herbert Sindermann, Medical Research and Development, Zentaris GmbH, Weismullerstrasse 50, 60314 Frankfurt, Germany, Telephone: 49-694-2602-2512, Fax: 49-694-2602-3404, E-mail: herbert.sindermann@zentaris.com. Philip J. Cooper, Laboratorio de Investigaciones, Hospital Pedro Vicente Maldonado, Pichincha Province, Casilla 17-14-30, Quito, Ecuador, Telephone: 593-98142216, Fax: 593-22-598009, E-mail: pcooper@cectec.ec.

REFERENCES


